F-DCFPyL
Phase 3Small molecule
F-DCFPyL is one of 97 small molecule programs targeting Metastasis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Metastatic Prostate Cancer
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Casodex
IIstituto Clinico Humanitas
Approved
Revia
TevaApproved
Zytiga
Johnson & JohnsonPhase 3
Xtandi
AstellasPhase 3
Taxotere
AAvyxa
Phase 3
Zoladex
TTerSera Therapeutics LLC
Approved
Erleada
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Jevtana
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastasis1 trial
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06756334·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-DCFPyL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details